News Sentiment

SION sentiment intelligence

Sionna Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 79 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 49.41 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 71

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+9.1% over one week, +32.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Sionna Therapeutics Inc. (SION) Stock Price | Live Quotes & Charts | NASDAQ

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 9.1% Price confirming higher
Trend fit Trend active 32.5% over four weeks
Fair value 68.1% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 48
Negative 10

Relevance

Why the article matched

Direct first
Direct company coverage 71
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
TradingView 8
Investing.com 4
Investing.com Nigeria 4
timothysykes.com 3
simplywall.st 3
Finviz 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 47
Earnings 20
Analyst action 6
Balance sheet 2
Deals and strategy 2
Regulatory and legal 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 79
Finviz Direct company coverage

SION - Sionna Therapeutics Inc Options

This article provides detailed financial data and performance metrics for Sionna Therapeutics Inc. (SION). It includes key financial figures such as market cap, income, sales, EPS, and various ratios, alongside stock performance, insider and institutional ownership, and analyst r

Tone
Negative 42/100
Event
Earnings
Published
01 Jul 2026 17:09
Source
Finviz
Finviz Direct company coverage

SION - Sionna Therapeutics Inc Short Interest

This article provides a detailed overview of Sionna Therapeutics Inc. (SION)'s short interest and key financial metrics. It includes stock performance data, insider and institutional ownership percentages, and analytical figures such as P/E ratios and debt/equity. The information

Tone
Negative 38/100
Event
Balance sheet
Published
01 Jul 2026 13:09
Source
Finviz
TradingView Direct company coverage

Price to sales forward of Sionna Therapeutics, Inc. – NASDAQ:SION

The article focuses on the "Price to sales forward" metric for Sionna Therapeutics, Inc. (NASDAQ: SION). It presents this financial data point within the context of the company's profile on TradingView, indicating its relevance for investors analyzing the biotechnology sector. Th

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 09:09
Source
TradingView
Seeking Alpha Direct company coverage

Sionna Therapeutics: NBD1 Stabilization Could Redefine Cystic Fibrosis Treatment (SION)

Sionna Therapeutics is developing a novel approach to treat cystic fibrosis by stabilizing NBD1, aiming to improve CFTR function beyond existing treatments. The company has two key drug candidates, SION-719 and SION-451, both nearing significant clinical data readouts in summer 2

Tone
Positive 75/100
Event
Market update
Published
30 Jun 2026 11:40
Source
Seeking Alpha
TradingView Direct company coverage

Price to earnings forward of Sionna Therapeutics, Inc. – NASDAQ:SION

This article provides a financial snapshot for Sionna Therapeutics, Inc. (NASDAQ:SION), focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of publication with no trades, and details are available under the "Financials" section. Th

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 22:11
Source
TradingView
marketscreener.com Direct company coverage

Sionna Therapeutics, Inc.(NasdaqGM:SION) dropped from Russell Microcap Growth Benchmark Index

Sionna Therapeutics, Inc. (NasdaqGM:SION) has been removed from the Russell Microcap Growth Benchmark Index, as reported on June 28, 2026. This follows other recent removals from related Russell indices. The company, a clinical-stage biopharmaceutical firm focusing on cystic fibr

Tone
Negative 33/100
Event
Market update
Published
29 Jun 2026 18:40
Source
marketscreener.com
www.marketscreener.com Direct company coverage

Sionna Therapeutics, Inc.(NasdaqGM: SION) dropped from Russell Microcap Index

Sionna Therapeutics, Inc. (NasdaqGM: SION) has been removed from the Russell Microcap Index. The company is a clinical-stage biopharmaceutical firm focused on developing novel medicines for cystic fibrosis, specifically small molecules designed to correct defects caused by the F5

Tone
Negative 39/100
Event
Market update
Published
29 Jun 2026 18:11
Source
www.marketscreener.com
TradingView Direct company coverage

Sionna Therapeutics, Inc. Actuals & Estimates (NASDAQ:SION)

This article provides an overview of Sionna Therapeutics, Inc. (SION) stock, including its current price, historical performance, and analyst forecasts. It also covers financial details such as market capitalization, upcoming earnings reports, past earnings, revenue, and net inco

Tone
Positive 70/100
Event
Earnings
Published
25 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

SION Forecast — Price Target — Prediction for 2027

This article provides a forecast for Sionna Therapeutics, Inc. (SION) stock, including analyst price targets, current stock performance, and financial data. It highlights that the stock has seen significant increases over the past year and details upcoming earnings dates, recent

Tone
Positive 70/100
Event
Analyst action
Published
25 Jun 2026 15:39
Source
TradingView
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO)

Three analysts have provided bullish insights on several healthcare companies. Gary Nachman of Canaccord Genuity reiterated a Buy rating for AbbVie (ABBV) with a $273 price target. Yatin Suneja of Guggenheim maintained a Buy rating on Sionna Therapeutics, Inc. (SION) with a $50 p

Tone
Positive 72/100
Event
Analyst action
Published
25 Jun 2026 05:40
Source
The Globe and Mail
Investing.com Nigeria Direct company coverage

Citizens reiterates Sionna Therapeutics stock rating ahead of summer data By Investing.com

Citizens has reaffirmed its Market Outperform rating and $63.00 price target for Sionna Therapeutics (NASDAQ: SION) ahead of key summer data readouts. The firm anticipates two significant readouts this summer that will influence the design of a Phase 2b cystic fibrosis trial, com

Tone
Neutral 50/100
Event
Analyst action
Published
24 Jun 2026 02:40
Source
Investing.com Nigeria